Get the Stockscreener App
103.22
0.29%
0.30
After Hours:
103.22
Mirum Pharmaceuticals Inc stock is traded at $103.22, with a volume of 805.34K.
It is up +0.29% in the last 24 hours and up +30.91% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$102.92
Open:
$102.85
24h Volume:
805.34K
Relative Volume:
1.10
Market Cap:
$6.18B
Revenue:
$379.25M
Net Income/Loss:
$-77.34M
P/E Ratio:
-64.02
EPS:
-1.6122
Net Cash Flow:
$-27.87M
1W Performance:
+9.47%
1M Performance:
+30.91%
6M Performance:
+101.92%
1Y Performance:
+113.09%
1-Day Range:
$100.62
$103.72
1-Week Range:
$93.23
$103.81
52-Week Range:
$36.88
$103.81
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
103.22 | 6.16B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | TD Cowen | Buy |
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Is Mirum Pharmaceuticals on a Strong Path to Profitability? - Finviz
Is Mirum Pharmaceuticals on a Strong Path to Profitability? - The Motley Fool
S P Trends: Is BLRX gaining market shareJuly 2025 Reactions & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Aug PreEarnings: Is Tronox Holdings plc impacted by rising ratesIndex Update & Trade Opportunity Analysis - baoquankhu1.vn
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $123.00 at Morgan Stanley - MarketBeat
Chronic hepatitis D market set for steady growth as pipeline inches forward - The Pharma Letter
H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? - Finviz
11 Best Stocks to Buy for Investment - Insider Monkey
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25% - simplywall.st
HC Wainwright Has Negative Outlook of MIRM FY2027 Earnings - MarketBeat
Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 - AOL.com
Heron Patrick J buys Mirum Pharmaceuticals shares worth $8.99m By Investing.com - Investing.com UK
Heron Patrick J buys Mirum Pharmaceuticals shares worth $8.99m - Investing.com
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 1,053 Shares of Stock - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells $302,325.17 in Stock - MarketBeat
Jolanda Howe Sells 842 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
Christopher Peetz Sells 6,831 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
3 Stocks That May Be Trading Below Estimated Value By Up To 48.2% - simplywall.st
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics - FinSMEs
Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline - Yahoo Finance
FY2030 Earnings Forecast for MIRM Issued By HC Wainwright - MarketBeat
Baird updates Mirum Pharmaceuticals (MIRM) valuation following beat-and-raise earnings results - MSN
Is Mirum Pharmaceuticals About to Soar in 2026? - Nasdaq
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
Aug Swings: What is the earnings history of Mirum Pharmaceuticals IncTrade Volume Report & Daily Technical Forecast Reports - baoquankhu1.vn
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics; Closes Private Placements of $268.5 Million - marketscreener.com
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - Investing News Network
H.C. Wainwright raises Mirum Pharmaceuticals stock price target on volixibat potential - Investing.com Canada
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Expert Outlook: Mirum Pharmaceuticals Through The Eyes Of 11 Analysts - Benzinga
Moving Averages: Does Mirum Pharmaceuticals Inc meet Warren Buffetts criteriaJuly 2025 Recap & AI Driven Stock Price Forecasts - baoquankhu1.vn
Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt Sells 1,421 Shares - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $86,423.58 in Stock - MarketBeat
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells 2,382 Shares of Stock - MarketBeat
Christopher Peetz Sells 7,098 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock - MarketBeat
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Sells $170,047.26 in Stock - MarketBeat
Mirum Pharmaceuticals CEO Sells Shares - TradingView
Mirum Pharmaceuticals stock hits all-time high at 95.75 USD By Investing.com - Investing.com Australia
Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results - Finviz
Mirum Pharmaceuticals stock hits all-time high at 95.75 USD - Investing.com
Mirum Pharmaceuticals, Inc. $MIRM Shares Acquired by Emerald Advisers LLC - MarketBeat
14 Best Mid-Cap Growth Stocks to Buy Right Now - Insider Monkey
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 52-Week HighHere's Why - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Joanne Quan Sells 6,911 Shares - MarketBeat
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? - sharewise.com
Mirum stock rises 7% in a week: Here's what you should know - MSN
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of "Buy" by Analysts - MarketBeat
23,566 Shares in Mirum Pharmaceuticals, Inc. $MIRM Bought by Campbell & CO Investment Adviser LLC - MarketBeat
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):